Alx Oncology Holdings (ALXO) Accounts Payables (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Accounts Payables data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 2.11% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 2.11% YoY), and the FY2025 full-year result was $4.9 million, up 9.27% from the prior year.
• Accounts Payables eased to $3.9 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $13.0 million in Q3 2023 to a low of $3.9 million in Q1 2026.
• A 5-year average of $6.7 million and a median of $6.2 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 121.11% in 2023, while the deepest fall reached 52.59% in 2023.
• Tracing ALXO's Accounts Payables over 5 years: stood at $8.1 million in 2022, then increased by 6.42% to $8.6 million in 2023, then sank by 47.65% to $4.5 million in 2024, then advanced by 9.27% to $4.9 million in 2025, then fell by 21.57% to $3.9 million in 2026.
• Business Quant data shows ALXO's Accounts Payables at $3.9 million in Q1 2026, $4.9 million in Q4 2025, and $6.6 million in Q3 2025.